These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 22504675)

  • 1. [Clinical development of PARP inhibitors].
    Toyoda M; Minami H
    Gan To Kagaku Ryoho; 2012 Apr; 39(4):519-24. PubMed ID: 22504675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology.
    Ratnam K; Low JA
    Clin Cancer Res; 2007 Mar; 13(5):1383-8. PubMed ID: 17332279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The potential of PARP inhibitors in genetic breast and ovarian cancers.
    Drew Y; Calvert H
    Ann N Y Acad Sci; 2008 Sep; 1138():136-45. PubMed ID: 18837894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [PARP inhibitors for cancer therapy].
    Saito H; Miki Y
    Gan To Kagaku Ryoho; 2011 Jan; 38(1):12-8. PubMed ID: 21368455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical poly(ADP-ribose) polymerase inhibitors for the treatment of cancer.
    Lewis C; Low JA
    Curr Opin Investig Drugs; 2007 Dec; 8(12):1051-6. PubMed ID: 18058575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic.
    Yap TA; Sandhu SK; Carden CP; de Bono JS
    CA Cancer J Clin; 2011; 61(1):31-49. PubMed ID: 21205831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of PARP in DNA repair and its therapeutic exploitation.
    Javle M; Curtin NJ
    Br J Cancer; 2011 Oct; 105(8):1114-22. PubMed ID: 21989215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases.
    Peralta-Leal A; Rodríguez-Vargas JM; Aguilar-Quesada R; Rodríguez MI; Linares JL; de Almodóvar MR; Oliver FJ
    Free Radic Biol Med; 2009 Jul; 47(1):13-26. PubMed ID: 19362586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PARP inhibitors in breast cancer: BRCA and beyond.
    Rios J; Puhalla S
    Oncology (Williston Park); 2011 Oct; 25(11):1014-25. PubMed ID: 22106552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poly(ADP-ribose) polymerase activity and inhibition in cancer.
    Dulaney C; Marcrom S; Stanley J; Yang ES
    Semin Cell Dev Biol; 2017 Mar; 63():144-153. PubMed ID: 28087320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks.
    Smith LM; Willmore E; Austin CA; Curtin NJ
    Clin Cancer Res; 2005 Dec; 11(23):8449-57. PubMed ID: 16322308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of poly(ADP-ribose) polymerase in cancer.
    Plummer ER
    Curr Opin Pharmacol; 2006 Aug; 6(4):364-8. PubMed ID: 16753340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PARP inhibitors for cancer therapy.
    Curtin NJ
    Expert Rev Mol Med; 2005 Mar; 7(4):1-20. PubMed ID: 15836799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of poly(ADP-ribosyl)ation in cancer: old and new paradigms revisited.
    Lupo B; Trusolino L
    Biochim Biophys Acta; 2014 Aug; 1846(1):201-15. PubMed ID: 25026313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The emerging role of poly(ADP-Ribose) polymerase inhibitors in cancer treatment.
    Sandhu SK; Yap TA; de Bono JS
    Curr Drug Targets; 2011 Dec; 12(14):2034-44. PubMed ID: 21777194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [PARP inhibitors: significant progress in cancer therapy].
    Dantzer F; Noel G; Schreiber V
    Bull Cancer; 2011 Mar; 98(3):277-90. PubMed ID: 21459712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PARP-1 inhibitors: a novel genetically specific agents for cancer therapy.
    Cipak L; Jantova S
    Neoplasma; 2010; 57(5):401-5. PubMed ID: 20568893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of PARP inhibitors in oncology.
    Rodon J; Iniesta MD; Papadopoulos K
    Expert Opin Investig Drugs; 2009 Jan; 18(1):31-43. PubMed ID: 19053880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PARP inhibitors in breast cancer.
    Telli ML; Ford JM
    Clin Adv Hematol Oncol; 2010 Sep; 8(9):629-35. PubMed ID: 21157412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer.
    Kyle S; Thomas HD; Mitchell J; Curtin NJ
    Br J Radiol; 2008 Oct; 81 Spec No 1():S6-11. PubMed ID: 18820000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.